Bionutrics snares Kirk for $12M

Generic drug developer Bionutrics is buying Kirk Pharmaceuticals for $12 million in cash and debt. Ronald H. Lane, PhD, Bionutrics' chairman and CEO, said, "This acquisition is an important step in the commercialization of Bionutrics' drug technology and further execution of our business plan. Kirk has relationships with some of the world's largest drug retailers and generic pharmaceutical companies and a growing manufacturing presence in the industry."

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.